✨ Free AI Report
Alnylam Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Alnylam Pharmaceuticals, Inc.
Company Research

Alnylam Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Alnylam Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Alnylam transitions from speculative biotech to profitable pharma leader with dominant RNAi platform and high-growth blockbuster in competitive ATTR market. The company achieved $3 billion in revenue with 81% growth year-over-year and reached profitability in 2025. For 2026, Alnylam's TTR franchise guidance of $4.4-4.7 billion represents 83% growth. However.

What is Alnylam Pharmaceuticals, Inc.'s industry? Alnylam Pharmaceuticals, Inc. (alnylam.com) operates in Biopharmaceuticals - RNA Interference (RNAi) Therapeutics. AskCyborg classifies Alnylam Pharmaceuticals, Inc. under Biopharmaceuticals - RNA Interference (RNAi) Therapeutics in its company registry.

Alnylam is the pioneer of RNA interference (RNAi) technology and has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the expansion of its flagship d...

8/ 10Strong

Cyborg Score thesis

Alnylam transitions from speculative biotech to profitable pharma leader with dominant RNAi platform and high-growth blockbuster...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - RNA Interference (RNAi) Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Alnylam Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Alnylam Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Alnylam Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Alnylam Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Alnylam Pharmaceuticals, Inc. Overview

Pro stress-test →

Alnylam is the pioneer of RNA interference (RNAi) technology and has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the expansion of its flagship drug, Amvuttra, into the multi-billion-dollar Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) market, the company is currently at the center of one of the most significant therapeutic shifts in modern medicine.

Strategic Profile

Pro stress-test →

With a blockbuster product in Amvuttra, a clear path to sustained profitability, and a platform expanding into massive therapeutic areas like hypertension and Alzheimer's, Alnylam is a rare breed in the biotechnology sector. The company's new five-year strategy, "Alnylam 2030," focuses on scaling operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility.

Competitive Landscape

Pro stress-test →

The "War of the TTRs" is the primary 2026 competitive narrative. Alnylam faces Pfizer (Vyndaqel as current market share leader), BridgeBio (Attruby as closest competitor), and Ionis/AstraZeneca (Wainua silencer with massive cardiovascular sales force). Alnylam's first-mover advantage and superior outcomes data position it as the company to beat.

Industry Context

Alnylam Pharmaceuticals, Inc. operates in Biopharmaceuticals - RNA Interference (RNAi) Therapeutics.

Key facts

Founded: 2002 · Headquarters: Cambridge, US · Revenue: $3.0B (2025)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Alnylam Pharmaceuticals, Inc..

  • Achieved profitability in 2025 after 15+ years of losses, marking transition to mature commercial-stage company
  • Amvuttra captured 83% of product revenue in Q4 2025 with strong payer coverage (90%+ first-line) positioning for sustained growth
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Reported $3B revenue (81% YoY growth) and achieved profitability for full year 2025
  • Jan 2026Announced Alnylam 2030 strategy targeting ATTR leadership, innovation growth, and financial discipline
  • +1 moreTrack every material event for Alnylam Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Alnylam Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

VyndaqelOral TTR stabilizer, current market leader in ATTR with 2028 patent expiration→AttrubyTTR stabilizer approved late 2024, closest competitor for first-line ATTR therapy→WainuaRNAi silencer with major advantage from AstraZeneca's cardiovascular sales force→

Compare Alnylam Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Alnylam Pharmaceuticals, Inc. operates in Biopharmaceuticals - RNA Interference (RNAi) Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - RNA Interference (RNAi) Therapeutics research →
NEW · MCP server

Ask your AI assistant about Alnylam Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Alnylam Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Alnylam Pharmaceuticals, Inc. do this quarter?”
“Is Alnylam Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Alnylam Pharmaceuticals, Inc. do?+
Alnylam is the pioneer of RNA interference (RNAi) technology and has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the expansion of its flagship d...
What is Alnylam Pharmaceuticals, Inc.'s Cyborg Score?+
Alnylam Pharmaceuticals, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Alnylam Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Vyndaqel, Attruby, Wainua. The full competitive landscape is in the AskCyborg report.
How can I get the full Alnylam Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Alnylam Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Alnylam Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - RNA Interference (RNAi) Therapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Alnylam Pharmaceuticals, Inc.